iSign Solutions (ISGN) 10-Q 14 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 14, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	iSign Solutions Inc.
Entity Central Index Key	0000727634
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Ex Transition Period	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,761,980
Entity File Number	000-19301
Entity Interactive Data Current	Yes
Entity Incorporation state Country Code	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 278	$ 335
Accounts receivable, net of allowance of $0 at June 30, 2019 and $1 at December 31, 2018, respectively	47	84
Prepaid expenses and other current assets	33	46
Total current assets	358	465
Property and equipment, net	3	2
Other assets	5	5
Total assets	366	472
Current liabilities:
Accounts payable	1,267	1,280
Short-term debt	2,230	2,210
Accrued compensation	75	81
Other accrued liabilities	665	524
Deferred revenue	426	281
Total current liabilities	4,663	4,376
Deferred revenue long-term		36
Other long-term liabilities	741	665
Total liabilities	5,404	5,077
Commitments and contingencies
Stockholders' equity (deficit):
Common stock, $0.01 par value; 2,000,000 shares authorized; 5,760 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	58	58
Treasury shares, 5 at June 30, 2019 and December 31, 2018, respectively	(325)	(325)
Additional paid-in capital	129,358	129,251
Accumulated deficit	(134,129)	(133,589)
Total stockholders' deficit	(5,038)	(4,605)
Total liabilities and stockholders' deficit	$ 366	$ 472

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance	$ 0	$ 1
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	2,000,000	2,000,000
Common stock, shares issued	5,760	5,760
Common stock, shares outstanding	5,760	5,760
Treasury shares	5	5

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue:
Product	$ 41	$ 34	$ 81	$ 73
Maintenance	186	192	344	367
Total revenue	227	226	425	440
Cost of sales:
Product	1	2	2	5
Maintenance	17	11	33	19
Research and development	181	238	352	466
Sales and marketing	27	42	53	61
General and administrative	190	153	395	328
Total operating costs and expenses	416	446	835	879
Loss from operations	(189)	(220)	(410)	(439)
Other income (expense), net	15	(44)	14	(44)
Interest expense:
Related party	(14)	(8)	(27)	(16)
Other	(49)	(34)	(96)	(64)
Amortization of debt discount:
Related party	(3)	(8)	(6)	(14)
Other	(7)	(20)	(14)	(38)
Loss before income tax expense	(247)	(334)	(539)	(615)
Income tax expense	(1)		(1)	(2)
Net loss	$ (248)	$ (334)	$ (540)	$ (617)
Basic and diluted net loss per common share	$ (0.04)	$ (0.06)	$ (0.09)	$ (0.11)
Weighted average common shares outstanding, basic and diluted	5,762	5,762	5,762	5,762

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulative Deficit	Total
Balance at Dec. 31, 2017	$ 58	$ (325)	$ 129,027	$ (132,562)	$ (3,802)
Balance, shares at Dec. 31, 2017	5,760	5
Stock based compensation			75		75
Net loss				(617)	(617)
Balance at Jun. 30, 2018	$ 58	$ (325)	129,102	(133,179)	(4,344)
Balance, shares at Jun. 30, 2018	5,760	5
Balance at Dec. 31, 2018	$ 58	$ (325)	129,251	(133,589)	(4,605)
Balance, shares at Dec. 31, 2018	5,760	5
Stock based compensation			107		107
Net loss				(540)	(540)
Balance at Jun. 30, 2019	$ 58	$ (325)	$ 129,358	$ (134,129)	$ (5,038)
Balance, shares at Jun. 30, 2019	5,760	5

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (540)	$ (617)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2	4
Debt discount amortization	20	52
Loss on disposal of fixed assets		7
Stock-based compensation	107	75
Changes in operating assets and liabilities:
Accounts receivable, net	37	(17)
Prepaid expenses and other assets	13	22
Accounts payable	(13)	11
Accrued compensation	(6)	(53)
Other accrued and long-term liabilities	217	220
Deferred revenue	109	46
Net cash used in operating activities	(54)	(250)
Cash flows from investing activities:
Acquisition of property and equipment	(3)
Net cash used in investing activities	(3)
Cash flows from financing activities:
Proceeds from the issuance of short-term debt		115
Payments on short-term debt		(40)
Net cash provided by financing activities		75
Net decrease in cash and cash equivalents	(57)	(175)
Cash and cash equivalents at beginning of period	335	285
Cash and cash equivalents at end of period	278	110
Supplementary disclosure of cash flow information
Interest paid		2
Income taxes paid	1	2
Non-cash financing and investing transactions:
Original issue discount on secured convertible promissory notes		$ 8

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Nature of Business and Summary of Significant Accounting Policies	1. Nature of Business and Summary of Significant Accounting Policies Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign’s solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign’s platform can be deployed both on premise and as a cloud-based (“SaaS”) service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company’s products include SignatureOne® Ceremony® Server, the iSign® suite of products and services, including iSign® Enterprise, iSign® Console™, and Sign-it® programs. Basis of Presentation The financial information contained herein should be read in conjunction with the Company’s consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2018. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at June 30, 2019, the Company’s accumulated deficit was $134,129. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of June 30, 2019, the Company’s cash balance was $278. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accounting Standards Update No. 2019-01, Leases (Topic 842), Codification Improvements. The amendments in this Update include the following items: (1) determining the fair value of the underlying asset by lessors that are not manufacturers or dealers; (2) presentation on the statement of cash flows—sales-type and direct financing leases; and (3) transition disclosures related to Topic 250, Accounting Changes and Error Corrections. The amendments in ASU 2019-01 for Issue 1 affect all lessors that are not manufacturers or dealers (generally financial institutions and captive finance companies); for Issue 2, all lessors that are depository and lending entities within the scope of Topic 942; for Issue 3, all entities that are lessees or lessors. The effective date of the amendments in ASU 2019-01 are for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2019-01 effective January 1, 2019. The adoption of ASU 2019-01 had no impact on the Company’s financial statements. Other Accounting Standards Updates issued in 2019 are not currently applicable to the Company, therefore implementation would not be expected to have a material impact on the Company’s financial position, results of operations and cash flows.

Concentrations

Concentrations	6 Months Ended
	Jun. 30, 2019
Risks and Uncertainties [Abstract]
Concentrations	2. Concentrations The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable Total Revenue Total Revenue 2019 2018 2019 2018 2019 2018 Customer #1 70 % 77 % 17 % 11 % 16 % 11 % Customer #2 − − 10 % 10 % 11 % 12 % Customer #3 − − 33 % 25 % 29 % 23 % Customer #4 − − 15 % 16 % 16 % 16 % Customer #5 21 % 15 % − − − − Customer #6 − − − − − 10 % Total concentration 91 % 92 % 75 % 62 % 72 % 72 %

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Net Loss per Share	3. Net Loss per Share The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted net income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding. The following table lists shares and warrants that were excluded from the calculation of diluted earnings per share as the inclusion of shares from the assumed exercise of such options and warrants would be anti-dilutive For the Three Months Ended For the Six Months Ended June 30, June 30, June 30, June 30, Stock options 1,077 726 1,077 726 Warrants 2,812 1,839 2,812 1,839

Debt

Debt	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Debt	5. Stockholders’ Equity (Deficit) Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended June 30, 2019 and 2018, was approximately 13.4% and 5.91%, respectively, based on historical data. Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized using the accrual method over the vesting period of the options. There were 40 stock options granted, and no stock options exercised during the three and six months ended June 30, 2019. The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three and six months ended June 30: Three Months Ended Six Months Ended 2019 2018 2019 2018 Research and development $ 8 $ 23 $ 17 $ 54 General and administrative $ 32 $ 1 $ 73 $ 14 Director and consultant options $ 8 $ 2 $ 17 $ 7 Total stock-based compensation expense $ 48 $ 26 $ 107 $ 75 A summary of option activity under the Company’s plans for the six months ended June 30, 2019 and 2018 is as follows: 2019 2018 Options Shares Weighted Weighted Aggregate Shares Weighted Weighted Aggregate Outstanding at January 1, 1,037 $ 1.65 − $ − 736 $ 3.65 $ − Granted 40 $ 0.50 − $ − − $ − $ − Forfeited or expired − $ − − $ − (10 ) $ 79.80 $ − Outstanding at June 30 1,077 $ 1.61 5.50 $ − 726 $ 2.56 5.94 $ − Vested and expected to vest at June 30 1,070 $ 1.61 5.50 $ − 696 $ 2.69 5.93 $ − Exercisable at June 30 489 $ 2.77 5.16 $ − 213 $ 7.50 5.32 $ − The following table summarizes significant ranges of outstanding and exercisable options as of June 30, 2019: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Weighted Number Weighted $0.01 – $0.50 655 5.27 $ 0.50 361 $ 0.50 $0.51 – $625.00 422 5.85 $ 3.33 128 $ 9.20 Total 1,077 5.50 $ 1.61 489 $ 2.77 A summary of the status of the Company’s non-vested shares as of June 30, 2019 is as follows: Non-vested Shares Shares Weighted Average Non-vested at January 1, 2019 718 $ 0.54 Granted 40 $ 0.50 Vested (170 ) $ 0.63 Non-vested at June 30, 2019 588 $ 0.64 As of June 30, 2019, there was a total of $149 of unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of 2.12 years. Warrants A summary of the warrant activity for the six months ended June 30 is as follows: 2019 2018 Shares Weighted Shares Weighted Outstanding at beginning of period 1,828 $ 2.08 1,878 $ 2.46 Issued 985 $ 0.50 − $ − Expired − $ − (39 ) $ 15.63 Outstanding at end of period 2,813 $ 1.53 1,839 $ 1.58 Exercisable at end of period 2,813 $ 1.53 1,839 $ 1.58 A summary of the status of the warrants outstanding and exercisable as of June 30, 2019 is as follows: Number of Warrants Weighted Weighted 1,550 1.91 $ 2.18 278 0.26 $ 1.63 985 2.64 $ 0.50 2,813 2.00 $ 1.53

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Stockholders' Equity (Deficit)	6. Stockholders' Equity (Deficit) Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended June 30, 2019 and 2018, was approximately 13.4% and 5.91%, respectively, based on historical data. Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized using the accrual method over the vesting period of the options. There were no stock options granted, and no stock options exercised during the three and six months ended June 30, 2019. The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three and six months ended June 30: Three Months Ended Six Months Ended 2019 2018 2019 2018 Research and development $ 8 $ 23 $ 17 $ 54 General and administrative $ 32 $ 1 $ 73 $ 13 Director and consultant options $ 8 $ 2 $ 17 $ 7 Total stock-based compensation expense $ 48 $ 26 $ 107 $ 74 A summary of option activity under the Company's plans for the six months ended June 30, 2019 and 2018 is as follows: 2019 2018 Options Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding at January 1, 1,037 $ 1.65 – $ 736 $ 3.65 $ – Granted 40 $ 0.50 – $ – $ – $ – Forfeited or expired – $ – – $ (10 ) $ 79.80 $ – Outstanding at June 30 1,077 $ 1.61 5.50 $ 726 $ 2.56 5.94 $ – Vested and expected to vest at June 30 1,070 $ 1.61 5.50 $ – 696 $ 2.69 5.93 $ – Exercisable at June 30 489 $ 2.77 5.16 $ – 213 $ 7.50 5.32 $ – The following table summarizes significant ranges of outstanding and exercisable options as of June 30, 2019: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Term Weighted Average Exercise Price per share Number Outstanding Weighted Average Exercise Price per Share $0.01 – $0.50 655 5.27 $ 0.50 361 $ 0.50 $0.511 –$625.00 422 5.85 $ 3.33 128 $ 9.20 Total 1,077 5.50 $ 1.61 489 $ 2.77 A summary of the status of the Company's non-vested shares as of June 30, 2019 is as follows: Non-vested Shares Shares Weighted Average Grant-Date Fair Value per share Non-vested at January 1, 2019 718 $ 0.64 Granted 40 $ 0.50 Vested (169 ) $ 0.63 Non-vested at June 30, 2019 589 $ 0.64 As of June 30, 2019, there was a total of $149 of unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of 2.12 years. Warrants A summary of the warrant activity for the six months ended June 30 is as follows: 2019 2018 Shares Weighted Average Exercise Price Per Share Shares Weighted Average Exercise Price Per Share Outstanding at beginning of period 1,827 $ 2.09 1,878 $ 2.46 Issued 985 $ 0.50 – $ – Expired – $ – (39 ) $ 15.63 Outstanding at end of period 2,812 $ 1.53 1,839 $ 1.58 Exercisable at end of period 2,812 $ 1.53 1,839 $ 1.58 A summary of the status of the warrants outstanding and exercisable as of June 30, 2019 is as follows: Number of Warrants Weighted Average Weighted Average 1,550 1.91 $ 2.18 277 0.26 $ 1.63 985 2.64 $ 0.50 2,812 2.00 $ 1.53

Nature of Business and Summar_2

Nature of Business and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Nature of Business	Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign's solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign's platform can be deployed both on premise and as a cloud-based ("SaaS") service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company's products include SignatureOne® Ceremony® Server, the iSign® suite of products and services, including iSign® Enterprise, iSign® Console™, and Sign-it® programs.
Basis of Presentation	Basis of Presentation The financial information contained herein should be read in conjunction with the Company’s consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2018. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year.
Going Concern	Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at June 30, 2019, the Company's accumulated deficit was $134,129. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of June 30, 2019, the Company's cash balance was $278. These factors raise substantial doubt about the Company's ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Accounting Changes and Recent Accounting Pronouncements	Accounting Changes and Recent Accounting Pronouncements (continued) Accounting Standards Update No. 2019-01, Leases (Topic 842), Codification Improvements. The amendments in this Update include the following items: (1) determining the fair value of the underlying asset by lessors that are not manufacturers or dealers; (2) presentation on the statement of cash flows—sales-type and direct financing leases; and (3) transition disclosures related to Topic 250, Accounting Changes and Error Corrections. The amendments in ASU 2019-01 for Issue 1 affect all lessors that are not manufacturers or dealers (generally financial institutions and captive finance companies); for Issue 2, all lessors that are depository and lending entities within the scope of Topic 942; for Issue 3, all entities that are lessees or lessors. The effective date of the amendments in ASU 2019-01 are for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2019-01 effective January 1, 2019. The adoption of ASU 2019-01 had no impact on the Company's financial statements. Other Accounting Standards Updates issued in 2019 are not currently applicable to the Company, therefore implementation would not be expected to have a material impact on the Company's financial position, results of operations and cash flows.

Concentrations (Tables)

Concentrations (Tables)	6 Months Ended
	Jun. 30, 2019
Risks and Uncertainties [Abstract]
Summary of accounts receivable and revenue concentrations	Accounts Receivable Total Revenue Total Revenue 2019 2018 2019 2018 2019 2018 Customer #1 70 % 77 % 17 % 11 % 16 % 11 % Customer #2 – – 10 % 10 % 11 % 12 % Customer #3 – – 33 % 25 % 29 % 23 % Customer #4 – – 15 % 16 % 16 % 16 % Customer #5 21 % 15 % – – – – Customer #6 – – – – – 10 % Total concentration 91 % 92 % 75 % 62 % 72 % 72 %

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Schedule of antidilutive excluded from calculation of earnings per share	For the Three Months Ended For the Six Months Ended June 30, June 30, June 30, June 30, Stock options 1,077 726 1,077 726 Warrants 2,812 1,839 2,812 1,839

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Schedule of allocation of stock-based compensation expense	Three Months Ended Six Months Ended 2019 2018 2019 2018 Research and development $ 8 $ 23 $ 17 $ 54 General and administrative $ 32 $ 1 $ 73 $ 14 Director and consultant options $ 8 $ 2 $ 17 $ 7 Total stock-based compensation expense $ 48 $ 26 $ 107 $ 75
Schedule of option activity under the Company's plans	2019 2018 Options Shares Weighted Weighted Aggregate Shares Weighted Weighted Aggregate Outstanding at January 1, 1,037 $ 1.65 − $ − 736 $ 3.65 $ − Granted 40 $ 0.50 − $ − − $ − $ − Forfeited or expired − $ − − $ − (10 ) $ 79.80 $ − Outstanding at June 30 1,077 $ 1.61 5.50 $ − 726 $ 2.56 5.94 $ − Vested and expected to vest at June 30 1,070 $ 1.61 5.50 $ − 696 $ 2.69 5.93 $ − Exercisable at June 30 489 $ 2.77 5.16 $ − 213 $ 7.50 5.32 $ −
Schedule of significant ranges of outstanding and exercisable options	Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Weighted Number Weighted $0.01 – $0.50 655 5.27 $ 0.50 361 $ 0.50 $0.51 – $625.00 422 5.85 $ 3.33 128 $ 9.20 Total 1,077 5.50 $ 1.61 489 $ 2.77
Schedule of the company's non-vested shares	Non-vested Shares Shares Weighted Average Non-vested at January 1, 2019 718 $ 0.54 Granted 40 $ 0.50 Vested (170 ) $ 0.63 Non-vested at June 30, 2019 588 $ 0.64
Schedule of warrant activity	2019 2018 Shares Weighted Shares Weighted Outstanding at beginning of period 1,828 $ 2.08 1,878 $ 2.46 Issued 985 $ 0.50 − $ − Expired − $ − (39 ) $ 15.63 Outstanding at end of period 2,813 $ 1.53 1,839 $ 1.58 Exercisable at end of period 2,813 $ 1.53 1,839 $ 1.58
Schedule of warrants outstanding and exercisable	Number of Warrants Weighted Weighted 1,550 1.91 $ 2.18 278 0.26 $ 1.63 985 2.64 $ 0.50 2,813 2.00 $ 1.53

Nature of Business and Summar_3

Nature of Business and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Nature of Business and Summary of Significant Accounting Policies (Textual)
Accumulated deficit	$ (134,129)	$ (133,589)
Cash balance	$ 278	$ 335	$ 110	$ 285

Concentrations (Details)

Concentrations (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Accounts Receivable [Member]
Concentration Risk [Line Items]
Total concentration			91.00%	92.00%
Accounts Receivable [Member] | Customer #1 [Member]
Concentration Risk [Line Items]
Total concentration			70.00%	77.00%
Accounts Receivable [Member] | Customer #2 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #3 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #4 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #5 [Member]
Concentration Risk [Line Items]
Total concentration			21.00%	15.00%
Accounts Receivable [Member] | Customer #6 [Member]
Concentration Risk [Line Items]
Total concentration
Total Revenue [Member]
Concentration Risk [Line Items]
Total concentration	75.00%	62.00%	72.00%	72.00%
Total Revenue [Member] | Customer #1 [Member]
Concentration Risk [Line Items]
Total concentration	17.00%	11.00%	16.00%	11.00%
Total Revenue [Member] | Customer #2 [Member]
Concentration Risk [Line Items]
Total concentration	10.00%	10.00%	11.00%	12.00%
Total Revenue [Member] | Customer #3 [Member]
Concentration Risk [Line Items]
Total concentration	33.00%	25.00%	29.00%	23.00%
Total Revenue [Member] | Customer #4 [Member]
Concentration Risk [Line Items]
Total concentration	15.00%	16.00%	16.00%	16.00%
Total Revenue [Member] | Customer #5 [Member]
Concentration Risk [Line Items]
Total concentration
Total Revenue [Member] | Customer #6 [Member]
Concentration Risk [Line Items]
Total concentration				10.00%

Net Loss Per Share (Details)

Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Stock options [Member]
Net Loss Per Share (Textual)
Anti-diluted earnings per share of stock options and warrants shares	1,077	726	1,077	726
Warrants [Member]
Net Loss Per Share (Textual)
Anti-diluted earnings per share of stock options and warrants shares	2,812	1,839	2,812	1,839

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended					3 Months Ended		6 Months Ended
	Dec. 31, 2018	Aug. 31, 2018	Jun. 30, 2018	May 31, 2018	Apr. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Aggregating amount of debt			$ 115	$ 115	$ 115
Debt instrument, description								Upon collection of an invoice, the Company would repay the advance to the lenders on a pro rata basis together with a 5% advance fee. The receivables were collected and $40 of the advances were repaid in May 2018, along with $2 in advance fees per the agreement. The advance fees were recorded as interest expense in the quarter ended June 30, 2018. The remaining $75 advances were converted into secured convertible notes in August 2018.
Secured notes due date								Dec. 31, 2019
Accrued interest expense						$ 63	$ 42	$ 123	$ 80
Accrued interest associated with the notes						54	34	107	66
Accrued interest to related parties						14	8	27	16
Accrued Interest to other investors						49	34	96	64
Amortization of debt discount						10	$ 28	20	$ 52
Unsecured notes						400		400
Accrued interest						$ 72		$ 72
Interest rate						10.00%		10.00%
Secured Convertible Promissory Notes [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Aggregating amount of debt	$ 346	$ 205
Debt instrument, description		The maturity date an additional 30% of the note's principal amount shall become due and payable.
Issued secured convertible promissory notes		$ 341
Conversion rate per shares	$ 0.50	$ 0.50
Aggregate proceeds of new financing	$ 1,000	$ 1,000
Secured notes bear interest rate	10.00%	10.00%
Secured notes due date	Dec. 31, 2019	Dec. 31, 2019
Original issue discounts		$ 61
Amount exchanged for advances		$ 75

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 48	$ 26	$ 107	$ 75
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	8	23	17	54
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	32	1	73	14
Director and consultant options [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 8	$ 2	$ 17	$ 7

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) (Details 1) - Option [Member] - USD ($) shares in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Shares
Outstanding, Beginning balance	1,037	736
Granted	40
Forfeited or expired		(10)
Outstanding, Ending Balance	1,077	726
Vested and expected to vest, Ending balance	1,070	696
Exercisable, Ending balance	489	213
Weighted Average Exercise Price Per share
Outstanding, Beginning balance	$ 1.65	$ 3.65
Granted	0.50
Forfeited/ Cancelled		79.80
Outstanding, Ending balance	1.61	2.56
Vested and expected to vest, Ending balance	1.61	2.69
Exercisable, Ending balance	$ 2.77	$ 7.50
Weighted Average Remaining Contractual Life (Years)
Outstanding, Ending balance	5 years 6 months	5 years 11 months 8 days
Vested and expected to vest, Ending balance	5 years 6 months	5 years 11 months 4 days
Exercisable, Ending balance	5 years 1 month 27 days	5 years 3 months 26 days
Aggregate Intrinsic Value
Outstanding, Beginning balance
Granted
Forfeited/ Cancelled
Outstanding, Ending balance
Vested and expected to vest, Ending balance
Exercisable, Ending balance

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) (Details 2) shares in Thousands	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	1,077
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	5 years 6 months
Options Outstanding, Weighted Average Exercise Price	$ 1.61
Options Exercisable, Number Outstanding | shares	489
Options Exercisable, Weighted Average Exercise Price	$ 2.77
$0.01 - $0.50 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	0.01
Range of Exercise Prices, Upper Range Limit	$ 0.50
Options Outstanding, Number Outstanding | shares	655
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	5 years 3 months 8 days
Options Outstanding, Weighted Average Exercise Price	$ 0.50
Options Exercisable, Number Outstanding | shares	361
Options Exercisable, Weighted Average Exercise Price	$ 0.50
$0.51 - $625.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	0.511
Range of Exercise Prices, Upper Range Limit	$ 625
Options Outstanding, Number Outstanding | shares	422
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	5 years 10 months 6 days
Options Outstanding, Weighted Average Exercise Price	$ 3.33
Options Exercisable, Number Outstanding | shares	128
Options Exercisable, Weighted Average Exercise Price	$ 9.20

Stockholders' Equity (Deficit_5

Stockholders' Equity (Deficit) (Details 3) shares in Thousands	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Shares
Non-vested, Beginning balance | shares	718
Granted | shares	40
Vested | shares	(170)
Non-vested, Ending balance | shares	588
Weighted Average Grant-Date Fair Value per share
Non-vested, Beginning balance | $ / shares	$ 0.54
Granted | $ / shares	0.50
Vested | $ / shares	0.63
Non-vested, Ending balance | $ / shares	$ 0.64

Stockholders' Equity (Deficit_6

Stockholders' Equity (Deficit) (Details 4) - Warrant [Member] - $ / shares shares in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Outstanding at beginning of period	1,828	1,878
Shares, Issued	985
Shares, Expired		(39)
Shares, Outstanding at end of period	2,813	1,839
Shares, Exercisable at end of period	2,813	1,839
Weighted Average Exercise Price Per Share, Outstanding at beginning of period	$ 2.08	$ 2.46
Weighted Average Exercise Price Per Share, Issued	0.50
Weighted Average Exercise Price Per Share, Expired		15.63
Weighted Average Exercise Price Per Share, Outstanding at end of period	1.53	1.58
Weighted Average Exercise Price Per Share, Exercisable at end of period	$ 1.53	$ 1.58

Stockholders' Equity (Deficit_7

Stockholders' Equity (Deficit) (Details 5) shares in Thousands	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Warrants | shares	2,813
Weighted Average Remaining Life (years)	2 years
Weighted Average Exercise Price per share | $ / shares	$ 1.53
Warrants Group One [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	1,550
Weighted Average Remaining Life (years)	1 year 10 months 28 days
Weighted Average Exercise Price per share | $ / shares	$ 2.18
Warrants Group Two [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	278
Weighted Average Remaining Life (years)	3 months 4 days
Weighted Average Exercise Price per share | $ / shares	$ 1.63
Warrants Group Three [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	985
Weighted Average Remaining Life (years)	2 years 7 months 21 days
Weighted Average Exercise Price per share | $ / shares	$ 0.50

Stockholders' Equity (Deficit_8

Stockholders' Equity (Deficit) (Details Textual) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Stockholders' Equity (Deficit) (Textual)
Total unrecognized compensation cost	$ 149
Weighted average period	2 years 1 month 13 days
Estimated average forfeiture rate	13.40%	5.91%